Thioredoxin reductase (TXNRD1) is overexpressed in lung cancer cells to maintain tumor survival, and this overexpression has been shown to be associated with clinical outcomes (Zhu et al., 2019). This evidence concerns the gene PRDX5 and neoplasm.